Evidence map›Paper›PMID 34715828›Full record

ReviewBMC endocrine disorders2021

Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.

Congxin Dai, Bowen Sun, Shusen Guan, Wei Wang, Honggang Liu, Yong Li, Jialiang Zhang, Jun Kang

Abstract readCase ReportsReview
In one paragraph

Review in BMC endocrine disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Congxin Dai *Department of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Bowen Sun *Department of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Shusen GuanDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100730, China.
Wei WangDepartment of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Honggang LiuDepartment of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Yong LiDepartment of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Jialiang ZhangDepartment of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
Jun KangDepartment of Neurosurgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China. kangjunty@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPituitary carcinomas (PCs), defined as distant metastases of pituitary neoplasms, are very rare malignancies. Because the clinical presentation of PCs is variable, early diagnosis and management remain challenging. PCs are always refractory to comprehensive treatments, and patients with PCs have extremely poor prognoses. CASE PRESENTATION: We describe one case of a prolactin-secreting pituitary adenoma (PA) refractory to conventional therapy that evolved into a PC with intraspinal metastasis. A 34-year-old female was diagnosed with an invasive prolactin-secreting PA in 2009 and was unresponsive to medical treatment with bromocriptine. The tumor was gross totally removed via transsphenoidal surgery (TSS). However, the patient experienced multiple tumor recurrences or regrowth despite comprehensive treatments, including medical therapy, two gamma knife radiosurgeries (GKSs), and four frontal craniotomies. In 2016, she was found to have an intradural extramedullary mass at the level of the fourth lumbar vertebra. The intraspinal lesion was completely resected and was confirmed as a metastatic PC based on histomorphology and immunohistochemical staining. The literature on the diagnosis, molecular pathogenesis, treatment, and prognosis of patients with prolactin-secreting PCs was reviewed.

conclusionPCs are very rare neoplasms with variable clinical features and poor prognosis. Most PCs usually arise from aggressive PAs refractory to conventional therapy. There is no reliable marker to identify aggressive PAs with a risk for progression to PCs; thus, it is difficult to diagnose these PCs early until the presence of metastatic lesions. It is still very challenging to manage patients with PCs due to a lack of standardized protocols for diagnosis and treatment. Establishing molecular biomarkers and the pathobiology of PCs could help in the early identification of aggressive PAs most likely to evolve into PCs.

Indexed as

AdultBromocriptineCarcinomaCraniotomyDisease ProgressionFemaleHormone AntagonistsHumansNeoplasm Recurrence, LocalNeurosurgical ProceduresPituitary NeoplasmsProlactinomaRadiosurgeryReoperationSpinal Cord NeoplasmsBromocriptineHormone AntagonistsIntraspinal metastasisInvasivePituitary carcinomasProlactin-secreting pituitary adenomasRecurrenceRefractory

Identifiers

PMID34715828
PMCPMC8555299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.